Pharmacies have been asked to implement controls on the supply of 150microgram adrenaline auto-injectors (AAIs) with immediate effect due to stock level issues reaching a “critical” stage.
All NHS and private prescriptions for 150microgram AAIs must now be validated before supply to pharmacies and dispensing doctors for a named patient from the wholesaler. NHS England has produced a flow chart setting out the validation process.
A statement said: “We have now reached a critical supply issue and need to implement controls on the supply of 150microgram adrenaline auto-injectors. Children weighing 25kg or less with the greatest short-term need must have access to these first, ensuring that every patient has at least one in date 150microgram adrenaline auto-injector. This can only be achieved by restricting issue of new devices until further notice.”
Pharmacies and dispensing doctors must clearly explain the situation to patients, parents and carers, NHS England says. The health body says it anticipates that more stock will be available at the end of the month.